ALLO
Price
$1.19
Change
+$0.01 (+0.85%)
Updated
Jun 30, 12:50 PM (EDT)
Capitalization
258.1M
37 days until earnings call
LRMR
Price
$2.90
Change
-$0.13 (-4.29%)
Updated
Jun 30, 02:14 PM (EDT)
Capitalization
194M
38 days until earnings call
Interact to see
Advertisement

ALLO vs LRMR

Header iconALLO vs LRMR Comparison
Open Charts ALLO vs LRMRBanner chart's image
Allogene Therapeutics
Price$1.19
Change+$0.01 (+0.85%)
Volume$100
Capitalization258.1M
Larimar Therapeutics
Price$2.90
Change-$0.13 (-4.29%)
Volume$200
Capitalization194M
ALLO vs LRMR Comparison Chart in %
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. LRMR commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a StrongBuy and LRMR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ALLO: $1.18 vs. LRMR: $3.03)
Brand notoriety: ALLO and LRMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 165% vs. LRMR: 141%
Market capitalization -- ALLO: $258.1M vs. LRMR: $194M
ALLO [@Biotechnology] is valued at $258.1M. LRMR’s [@Biotechnology] market capitalization is $194M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileLRMR’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • LRMR’s FA Score: 1 green, 4 red.
According to our system of comparison, LRMR is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 3 TA indicator(s) are bullish while LRMR’s TA Score has 6 bullish TA indicator(s).

  • ALLO’s TA Score: 3 bullish, 6 bearish.
  • LRMR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, LRMR is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а -4.07% price change this week, while LRMR (@Biotechnology) price change was +16.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.10%. For the same industry, the average monthly price growth was +33.47%, and the average quarterly price growth was +7.38%.

Reported Earning Dates

ALLO is expected to report earnings on Aug 06, 2025.

LRMR is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($258M) has a higher market cap than LRMR($194M). LRMR YTD gains are higher at: -21.705 vs. ALLO (-44.601). LRMR has higher annual earnings (EBITDA): -105.02M vs. ALLO (-238.37M). ALLO has more cash in the bank: 280M vs. LRMR (158M). LRMR has less debt than ALLO: LRMR (4.87M) vs ALLO (81.3M). ALLO (0) and LRMR (0) have equivalent revenues.
ALLOLRMRALLO / LRMR
Capitalization258M194M133%
EBITDA-238.37M-105.02M227%
Gain YTD-44.601-21.705205%
P/E RatioN/AN/A-
Revenue00-
Total Cash280M158M177%
Total Debt81.3M4.87M1,671%
FUNDAMENTALS RATINGS
ALLO vs LRMR: Fundamental Ratings
ALLO
LRMR
OUTLOOK RATING
1..100
5850
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
22
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6539
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (22) in the null industry is significantly better than the same rating for ALLO (97) in the Biotechnology industry. This means that LRMR’s stock grew significantly faster than ALLO’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as ALLO (100) in the Biotechnology industry. This means that LRMR’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (97) in the Biotechnology industry is in the same range as LRMR (100) in the null industry. This means that ALLO’s stock grew similarly to LRMR’s over the last 12 months.

LRMR's Price Growth Rating (39) in the null industry is in the same range as ALLO (65) in the Biotechnology industry. This means that LRMR’s stock grew similarly to ALLO’s over the last 12 months.

LRMR's P/E Growth Rating (100) in the null industry is in the same range as ALLO (100) in the Biotechnology industry. This means that LRMR’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOLRMR
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
89%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
82%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 28 days ago
80%
Bullish Trend 6 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
81%
Aroon
ODDS (%)
Bullish Trend 4 days ago
68%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USAWX31.780.18
+0.57%
Victory Sustainable World
CBLLX10.840.06
+0.56%
Allspring Large Cap Value Admin
PMYTX45.080.25
+0.56%
Putnam Core Equity Fund R6
HESAX43.170.23
+0.54%
Horizon Defensive Core Advisor
FSZZX10.18-0.01
-0.10%
Fidelity Advisor Sustainable EM Eq Z

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
-1.67%
CRSP - ALLO
63%
Loosely correlated
+1.69%
FATE - ALLO
57%
Loosely correlated
-5.45%
NTLA - ALLO
53%
Loosely correlated
-0.52%
BEAM - ALLO
53%
Loosely correlated
-1.98%
RXRX - ALLO
49%
Loosely correlated
-6.85%
More

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with ERAS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
-1.62%
ERAS - LRMR
53%
Loosely correlated
+3.97%
IMNM - LRMR
50%
Loosely correlated
-0.23%
ATXS - LRMR
49%
Loosely correlated
+2.39%
ACLX - LRMR
48%
Loosely correlated
+0.90%
SYRE - LRMR
48%
Loosely correlated
-4.99%
More